Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in @NEJM today.
In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.
Some thoughts on this ground breaking trial:
🧵/ Our new total CV risk prediction tool, Predicting Risk of CV disease EVENTS (PREVENT) is now available: https://t.co/lYWLcBFPhy
The calculator predicts risk for heart attack, stroke & heart failure.
✍🏽 @HeartDocSadiya @JoeCoresh @dmljmd@ChiadiNdumele@RangaswJ
More ⬇️🧵
Manage Cardiogenic Shock 2/2 Acute Myocardial Infarction like a pro! This is the (updated) protocol we’ve been using to manage ICU patients for years with fantastic results. 🎩 tip to the authors!
https://t.co/4Ise540F2X
Pretreatement with #P2Y12 inhibitors in #STEMI patients! An analysis of 1,116 patients in the Bern-PCI registry demonstrated that pretreatment did not impact #MACE, stent thrombosis, #bleeding or procedural aspects 🫀 https://t.co/XZLh6gWxRS
#JACCINT#P2Y12i#PCI
false positive EST not due to poor specificity of EST as a diagnostic test but from using obstructive CAD as reference standard for myocardial ischemia
When CMD by invasive physiological assessment used as reference standard,EST has 💯specificity https://t.co/44irzoXa2i
Frail AF is an excellent trial--w a surprising result that informs practice tomorrow
Great presentation from Dr. Linda Joosten
Take homes: 1) Be careful translating evidence to older pts with co-morbid conditions 2) Study uncertainties in RCTs -- it can be done #escccongress
The ACC has developed the point of care #ultrasound workbook to provide guidance on using POCUS in CV clinical practice.
🔑Key Points from the #POCUS Workbooks⬇️
1/ #HFpEF treatment algorithm #tweetorial. This is the algorithm I currently use to treat HFpEF based on evidence we have thus far and my anecdotal experience treating patients over the past 16 years in the @NMCardioVasc HFpEF Clinic.
TOP 10 CARDIAC ARREST TRIALS OF 2022 🫀⚡️
What a year for resuscitation science! 💥
➡️ I collected and summarized in this infographic 10 must-read randomized trials published in 2022 in the fields of cardiac arrest and CPR
🔗 https://t.co/KUpXJo4u59
#FOAMcc#ResusTwitter
New cluster RCT in OHCA
🚑 DSED or vector-change in refractory VF
👉 Double sequential external defibrillation (rapid sequential shocks from 2 defibrillators) or switching pads to an A-P position
➡️ Higher survival for both techniques
🔗 https://t.co/5EdHOul5J4
#ResusTwitter
#AHA22 LBCTs one liners:
1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.
2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.
UPDATE: We're excited to announce that all Oklahomans will be eligible to receive the COVID-19 vaccine starting March 29. We encourage everyone to make an appointment for their vaccine as soon as possible through any of the available methods.